Chengmai Ruan

Title: Chengmai Ruan: Innovator in Pharmaceutical Compounds

Introduction

Chengmai Ruan is a notable inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target metabolic disorders. With a total of 2 patents, his work has the potential to impact the treatment of conditions such as hyperglycemia and type II diabetes mellitus.

Latest Patents

Ruan's latest patents include innovative compounds that serve as agonists for hPPAR alpha and hPPAR gamma. The first patent describes tyrosine derivatives substituted by N-arylacryloyl, which are used in the preparation of medicaments for treating hyperglycemia and dyslipidemia. The second patent focuses on substituted α-piperazinyl phenylpropionic acid derivatives, which also act as agonists for hPPAR alpha and/or hPPAR gamma, aimed at similar therapeutic applications.

Career Highlights

Throughout his career, Chengmai Ruan has worked with prominent companies such as Beijing Molecule Science Technology Co., Ltd. and Beijing Molecule Science and Technology Co., Ltd. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation and development.

Collaborations

Ruan has collaborated with notable colleagues in his field, including Song Li and Xinbo Zhou. These partnerships have likely contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Chengmai Ruan stands out as an influential inventor in the pharmaceutical industry, with a focus on developing innovative treatments for metabolic disorders. His contributions through patents and collaborations highlight his commitment to advancing medical science.